KORU Medical Systems (KRMD) to Announce Quarterly Earnings on Wednesday

KORU Medical Systems (NASDAQ:KRMD) is expected to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect KORU Medical Systems to post earnings of ($0.02) per share and revenue of $11.6180 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

KORU Medical Systems Stock Performance

KRMD opened at $4.11 on Monday. The stock has a 50-day moving average of $4.12 and a 200 day moving average of $4.42. KORU Medical Systems has a 12 month low of $3.20 and a 12 month high of $6.61. The firm has a market cap of $188.78 million, a P/E ratio of -82.20 and a beta of 0.41.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Weiss Ratings raised KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Wall Street Zen raised KORU Medical Systems from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Insider Activity

In other news, insider Adam R. Kalbermatten bought 12,500 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average price of $3.94 per share, for a total transaction of $49,250.00. Following the acquisition, the insider owned 312,500 shares of the company’s stock, valued at $1,231,250. The trade was a 4.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have bought 28,000 shares of company stock valued at $109,430. 18.50% of the stock is currently owned by company insiders.

Institutional Trading of KORU Medical Systems

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares during the period. Lazard Asset Management LLC bought a new stake in shares of KORU Medical Systems during the 2nd quarter worth approximately $59,000. Acadian Asset Management LLC bought a new stake in shares of KORU Medical Systems during the 1st quarter worth approximately $63,000. Invesco Ltd. purchased a new position in KORU Medical Systems during the 2nd quarter valued at $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in KORU Medical Systems during the 2nd quarter valued at $83,000. Institutional investors own 58.60% of the company’s stock.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.